Peripheral Neuropathy Clinical Trial
— CMT4JOfficial title:
A Prospective Natural History and Outcome Measure Discovery Study of Charcot-Marie-Tooth Disease, Type 4J
This is a multicenter, longitudinal, prospective observational natural history study of subjects with a molecularly confirmed diagnosis of CMT4J. The study will enroll 20 subjects of any age into a uniform protocol for follow-up and evaluations. Subject visits will occur every 12 months + 4 weeks for up to 2 years.
Status | Not yet recruiting |
Enrollment | 20 |
Est. completion date | March 1, 2028 |
Est. primary completion date | March 1, 2027 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion Criteria: 1. Male or female, all ages 2. A molecularly-confirmed diagnosis of CMT4J (confirmed by a CLIA certified, CE-marked, or equivalent lab): Genomic DNA mutation analysis demonstrating 1) bi-allelic pathogenic and/or likely pathogenic variants (by ACMG criteria) in the FIG4 gene, or 2) bi-allelic variants with one pathogenic and/or likely pathogenic variant in trans with a variant of uncertain significance if laboratory evidence and expert consensus exits in support of loss of FIG4 function exists. 3. Informed consent from patients 18 years or older who are able to provide consent and from caregivers; parent(s)/guardian(s) providing consent for subjects younger than 18 years at Screening and patients older than 18 years unable to provide informed consent 4. Informed assent of patients younger than 18 years at Screening who are able to provide assent 5. Able and willing to comply with the study protocol, including travel to Study Center, procedures, measurements and visits Exclusion Criteria: 1. Any known genetic abnormality, including chromosomal aberrations that confound the clinical phenotype 2. Current participation in an interventional or therapeutic study 3. Receiving an investigational drug within 90 days of the Baseline Visit 4. Prior or current treatment with gene or stem cell therapy 5. Any other diseases which may significantly interfere with the assessment of CMT4J 6. Have any other conditions, which, in the opinion of the Investigator or Sponsor would make the subject unsuitable for inclusion or could interfere with the subject participating in or completing the study |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Elpida Therapeutics SPC |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Study objective | This study is designed to investigate the clinical characteristics and natural history of CMT4J. | 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05152368 -
Safety of Cultured Allogeneic Adult Umbilical Cord Stem Cells for Trigeminal Neuralgia and Peripheral Neuropathy
|
Phase 1 | |
Completed |
NCT05647083 -
The Effect of Massage on Diabetic Parameters
|
N/A | |
Completed |
NCT02549534 -
Early Detection of Taxane-Induced Neuropathy in Women With Breast Cancer
|
N/A | |
Active, not recruiting |
NCT02701075 -
MC5-A Scrambler Therapy for the Treatment of Chronic Neuropathic Extremity Pain
|
N/A | |
Completed |
NCT01196442 -
Electrical Stimulation Pain Therapy in Treating Chronic Pain and Numbness Caused By Chemotherapy in Patients With Cancer
|
N/A | |
Completed |
NCT00763087 -
Effect of Weight-Bearing Exercise on People With Diabetes and Neuropathic Feet
|
N/A | |
Completed |
NCT00079807 -
Painful HIV Neuropathy and Alpha-Lipoic Acid
|
Phase 1/Phase 2 | |
Completed |
NCT03292328 -
Yoga for Symptoms of Nerve Damage Caused by Chemotherapy
|
N/A | |
Active, not recruiting |
NCT05379140 -
Use Therapeutic Chinese Massage to Treat Peripheral Neuropathy in People With HIV
|
N/A | |
Recruiting |
NCT05673746 -
Acupuncture in Chemotherapy-induced Peripheral Neuropathy in Women With Breast Cancer
|
N/A | |
Completed |
NCT05189535 -
"Prevention of Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer Patients"
|
Phase 2/Phase 3 | |
Recruiting |
NCT06219590 -
Acetylcholine Iontophoresis As A New Challenge With Type 2 Diabetic Peripheral Neuropathy: A Possible New Therapy
|
N/A | |
Enrolling by invitation |
NCT05595109 -
Role of Silymarin in Chemotherapy Toxicity and Cognition Improvement in Breast Cancer Patients
|
Phase 2/Phase 3 | |
Completed |
NCT05916118 -
Exercise and Oxaliplatin-induced Peripheral Neuropathy
|
N/A | |
Withdrawn |
NCT03881748 -
Clinical Trial of Acupuncture for Chemotherapy-Induced Peripheral Neuropathy
|
N/A | |
Not yet recruiting |
NCT03112057 -
Visualize Nociceptor Changes in Neuropathic Human
|
N/A | |
Completed |
NCT02936843 -
Targeting Inflammation With Salsalate in Type 1 Diabetes Neuropathy
|
Phase 2/Phase 3 | |
Terminated |
NCT01458015 -
Tapentadol Versus Oxycodon - a Mechanism-based Treatment Approach in Neuropathic Pain
|
Phase 4 | |
Completed |
NCT01006408 -
Treatment Trial Using Low Level Laser Therapy (LLLT) for Treatment of Chemotherapy Induced Peripheral Neuropathy
|
N/A | |
Completed |
NCT00471445 -
Topical Amitriptyline and Ketamine Cream in Treating Peripheral Neuropathy Caused by Chemotherapy in Cancer Patients
|
Phase 3 |